What is Pre-Exposure Prophylaxis and how does it prevent HIV?
Pre-Exposure Prophylaxis, commonly known as PrEP, represents one of the most significant advancements in the global effort to prevent the spread of HIV. It is a biomedical intervention designed for individuals who do not have HIV but who are at an elevated risk of acquiring the virus through sexual exposure or injection drug use. When taken as prescribed, PrEP is extraordinarily effective, reducing the risk of getting HIV from sex by about 99 percent.
The concept of prophylaxis is straightforward: it means taking a medication beforehand to prevent a disease from taking hold. The most common oral PrEP medications combine two active antiretroviral drugs in a single pill—specifically, emtricitabine and a form of tenofovir. These are the exact same medications used to treat people who already have HIV, but in the context of PrEP, they are used to build a defensive shield in the body.
To understand how it works, imagine HIV entering the bloodstream of an HIV-negative person. The virus’s immediate goal is to find a CD4 immune cell, enter it, and use an enzyme called reverse transcriptase to copy its genetic material and establish a permanent infection. If that person is taking PrEP, the emtricitabine and tenofovir are already waiting inside the CD4 cells. These drugs act as faulty building blocks. When the virus attempts to use its reverse transcriptase enzyme to copy itself, it picks up these faulty blocks instead. The copying process abruptly halts, the virus cannot replicate, and it is ultimately cleared by the body before an infection can be established. PrEP essentially stops the virus in its tracks at the very first step.
The difference between Truvada and Descovy formulations
If you are exploring oral PrEP options, you will likely encounter two primary medications: one containing tenofovir disoproxil fumarate (TDF) combined with emtricitabine, and a newer option containing tenofovir alafenamide (TAF) combined with emtricitabine. Historically, these were branded as Truvada and Descovy, respectively, though generic versions of the TDF formulation are now widely available globally.
Both medications are highly effective at preventing HIV. The difference lies entirely in the formulation of the tenofovir component and its corresponding safety profile. TDF, the older formulation, is safe for the vast majority of people, but long-term use can occasionally cause slight decreases in kidney function and small reductions in bone mineral density. The newer formulation, TAF, was engineered to deliver the active drug more directly into the immune cells. Because it is highly targeted, much less of the drug circulates freely in the bloodstream, resulting in less exposure to the kidneys and bones.
Clinical trials showed that the TAF formulation has a slightly more favourable profile regarding renal and bone safety markers. However, it is important to note that TAF has been associated with slight weight gain and modest increases in cholesterol levels compared to TDF. Additionally, the TAF formulation (Descovy) is currently only approved for individuals at risk of HIV through sexual exposure excluding those assigned female at birth who are at risk from vaginal sex, as trials in that specific population have not yet been completed. Your prescriber will help you weigh your kidney and bone health history against these factors to choose the formulation that is right for you.
Understanding daily dosing and the importance of adherence
The traditional and most universally recommended method of taking PrEP is as a single daily pill. This daily dosing strategy is approved for all populations at risk of HIV, including men who have sex with men, transgender women, heterosexual men and women, and people who inject drugs.
When you take the pill every day, the medication builds up to maximum protective levels in your bodily tissues. Specifically, it takes about seven days of daily dosing for the drugs to reach maximum protective levels in rectal tissues, and approximately twenty-one days of daily dosing to reach maximum protection in blood and vaginal tissues. Once these optimal levels are reached, the daily dose simply maintains that protective shield around the clock.
The effectiveness of daily PrEP is entirely dependent on adherence. Studies have definitively shown that the medication only works if you take it. If doses are frequently missed, the level of medication in the tissues drops, and the protective shield weakens, allowing a window for the virus to establish an infection. While missing a single dose occasionally will not completely eliminate protection in someone who has been highly adherent for months, creating a rock-solid daily habit is the best way to ensure you are receiving the 99 percent risk reduction that PrEP promises.
The emergence of on-demand or event-driven dosing
For some individuals, taking a daily medication for HIV prevention feels unnecessary, especially if their sexual encounters are infrequent or highly predictable. To address this, researchers developed an alternative strategy known as ‘on-demand’, ‘event-driven’, or ‘2-1-1’ dosing. This strategy is currently recommended by many major health organizations specifically for men who have sex with men; it is not yet recommended for cisgender women or transgender men having frontal/vaginal sex due to differences in how the drug concentrates in those tissues.
The 2-1-1 method provides a precise schedule for taking the medication only around the time of sexual activity. It involves taking two pills between two and twenty-four hours before a sexual encounter. This double ‘loading dose’ rapidly spikes the medication levels in the blood and rectal tissues. Then, you take one pill exactly 24 hours after the first dose, and a final fourth pill exactly 48 hours after the first dose. If sexual activity continues for multiple days, you continue taking one pill every 24 hours until two days have passed since the last sexual encounter.
Clinical trials, such as the IPERGAY study, demonstrated that this event-driven strategy is highly effective for men who have sex with men, offering protection on par with daily dosing when followed strictly. It offers a fantastic alternative for individuals who want robust protection but prefer not to be tied to a daily medication regimen. However, it requires careful planning and the ability to strictly adhere to the timed dosing schedule.
Managing side effects like nausea and the ‘PrEP startup syndrome’
Like any medication, PrEP can cause side effects. Fortunately, the vast majority of people who take emtricitabine/tenofovir experience no side effects whatsoever. For those who do, the side effects are typically mild and transient, occurring primarily during the first few weeks of taking the medication—a period often referred to colloquially as ‘PrEP startup syndrome.’
The most commonly reported start-up symptoms include mild nausea, stomach upset, flatulence, headache, and fatigue. These symptoms occur as the body adjusts to the presence of the antiretroviral drugs. They almost always resolve on their own within the first two to four weeks. If you experience nausea, taking the pill with a meal or right before bed can often significantly reduce the discomfort.
It is crucial not to stop taking PrEP simply because of these mild initial side effects. If you stop the medication, you lose the protective benefit. If the side effects are persistent or genuinely disruptive to your daily life, speak with your healthcare provider. They can offer strategies to manage the symptoms or discuss if an alternative prevention method might be better suited to your body. Severe side effects are exceedingly rare, but as with all medications, any severe or concerning symptom should prompt immediate medical consultation.
Why regular clinical monitoring and testing is mandatory
Getting a prescription for PrEP is not a one-time event; it is the beginning of an ongoing relationship with a healthcare provider. Taking PrEP safely and effectively requires a commitment to regular, mandatory clinical monitoring, typically occurring every three months.
The most critical component of this monitoring is repeat HIV testing. PrEP must never be taken by someone who already has HIV. If a person with an undiagnosed HIV infection takes PrEP (which contains only two active drugs), the virus will rapidly mutate and become resistant to those drugs, severely limiting their future treatment options. Therefore, an HIV test is mandatory before starting PrEP, and every three months while taking it, to ensure you remain HIV-negative.
In addition to HIV testing, these quarterly visits are used to screen for other sexually transmitted infections (STIs), such as syphilis, gonorrhoea, and chlamydia. PrEP only protects against HIV; it offers zero protection against other STIs. Regular screening ensures that any acquired infections are diagnosed and treated promptly, protecting both your health and the health of your partners. Your provider will also periodically check your kidney function via a simple blood test to ensure the tenofovir is not causing any stress to your renal system.
How PrEP fits into a broader sexual health strategy
It is helpful to view PrEP not as a magical shield, but as one highly effective tool within a broader, comprehensive approach to sexual health. Because PrEP does not prevent other sexually transmitted infections or pregnancy, it is often most effective when combined with other protective strategies.
Many individuals choose to use condoms alongside PrEP. Condoms provide excellent protection against many bacterial STIs, such as gonorrhoea and chlamydia, and offer a secondary layer of protection against HIV. This combination approach is particularly recommended for individuals who have multiple partners or whose partners’ STI status is unknown.
Furthermore, taking PrEP requires taking control of your sexual health. It involves regular STI testing, open conversations with healthcare providers, and a commitment to your own well-being. The quarterly clinic visits provide an excellent opportunity to discuss any concerns you have about your sexual health, access vaccinations for HPV or Hepatitis A and B, and receive non-judgmental support and education.
Overcoming stigma and discussing PrEP with your provider
Despite its proven efficacy, stigma remains a significant barrier to PrEP access. Some individuals feel embarrassed to ask for the medication, fearing they will be judged for their sexual behaviour. Unfortunately, this stigma is sometimes perpetuated by a lack of education or implicit bias within the healthcare system itself.
It is crucial to remember that taking PrEP is a highly responsible, proactive choice. It is a commitment to protecting yourself and your community from a serious virus. You have every right to access preventative healthcare without judgement. When discussing PrEP with a provider, be honest about your sexual practices; healthcare professionals need accurate information to provide the best care.
If you encounter a provider who is dismissive, uneducated about PrEP, or judgemental, you have the right to seek a second opinion. There are numerous sexual health clinics, specialized community organizations, and telehealth services that specialize in non-judgmental, accessible PrEP prescribing. Do not let stigma or an uncomfortable conversation deter you from accessing a medication that could protect your long-term health and provide profound peace of mind.
This article is for informational purposes only and is not a substitute for medical advice from a licensed healthcare professional. Always consult your doctor or pharmacist before starting, changing, or stopping any medication.